Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety, Tolerability, and Proof-of-Concept Efficacy of Lisinopril in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS), Stage 1

Trial Profile

Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety, Tolerability, and Proof-of-Concept Efficacy of Lisinopril in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS), Stage 1

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Lisinopril (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Transparency Life Sciences
  • Most Recent Events

    • 16 Oct 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2018.
    • 21 Oct 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Mar 2017.
    • 12 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top